SYNTEX PHARMACEUTICAL OPERATIONS AND IS PAUL FREIMAN, who was named by company to run the drug business as part of a management reorganization in the wake of the departure of Syntex President Richard Rogers. "Paul E. Freiman will become exec VP of Syntex, responsible for managing the worldwide pharmaceuticals and agribusiness operations," the firm said in an Oct. 30 press release. Freiman, who will also be a candidate for election to Syntex' board at the annual shareholder meeting Dec. 13, will assume responsibility for the drug business from Ian McDonald, who retired in August. In addition, Corporate VP and President of Syntex Diagnostics Div. Thomas Gutshall will become senior VP of Syntex responsible for management of the diagnostics div., the chemical operations and technical services group as well as Syntex Dental Products. The release notes that both Gutshall and Freiman will report directly to Chairman and CEO Albert Bowers, PhD, in their new roles. Together, they will share some of the responsibilities held by Rogers, who is retiring at the end of 1985. At that time Bowers will assume the additional title of president ("The Pink Sheet" Sept. 30, In Brief). Named to the newly created positions of vice chairman of the Syntex board of directors are John Fried, PhD, and Hans Wolf. The release notes that Fried will also continue as president of Syntex Research and Wolf will continue as chief administrative officer. In addition, Alan Jarrett, senior VP of human resources will continue as acting president of Syntex Ophthalmics. "I am confident that this restructuring of our management team will place us in a strong position to meet the challenges and opportunities we see ahead, especially as we prepare to introduce potentially major new pharmaceutical products," Bowers said. A registered pharmacist and a Syntex employee for the last 27 years, Frieman was most recently senior VP human pharmaceuticals, responsible for the company's worldwide drug business, which accounts for roughly two-thirds of corporate sales. Prior to that he served as VP, western hemisphere-Pacific region. Gutshall served as president of Syva, the largest subsidiary of the Syntex Diagnostics Div., from 1981 until recently. Before that he held the position of group VP Syntex U.S.A., in charge of engineering, production technical services and pharmaceutical chemical manufacturing.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
